Evaluation of masitinib in the treatment of Progressive Supranuclear Palsy
A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP) A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/ ...
Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Pro ...
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...